OncoZenge Valuation

Is ONCOZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONCOZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ONCOZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ONCOZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONCOZ?

Key metric: As ONCOZ barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ONCOZ. This is calculated by dividing ONCOZ's market cap by their current book value.
What is ONCOZ's PB Ratio?
PB Ratio	3.3x
Book	SEK 12.45m
Market Cap	SEK 40.94m

ONCOZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11702.6x
Enterprise Value/EBITDA	4.8x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ONCOZ's PB Ratio compare to its peers?

The above table shows the PB ratio for ONCOZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.6x
ACUC AcuCort	2x	n/a	SEK 99.9m
PMED PEPTONIC medical	1.2x	n/a	SEK 92.1m
NEWBRY Newbury Pharmaceuticals	1.6x	130.0%	SEK 80.5m
LIPI Lipidor	5.8x	n/a	SEK 95.2m
ONCOZ OncoZenge	3.3x	93.3%	SEK 40.9m

Price-To-Book vs Peers: ONCOZ is expensive based on its Price-To-Book Ratio (3.3x) compared to the peer average (2.6x).

Price to Book Ratio vs Industry

How does ONCOZ's PB Ratio compare vs other companies in the SE Pharmaceuticals Industry?

5 Companies	Price / Book	Estimated Growth	Market Cap
KDEV Karolinska Development	0.2x	5.8%	US$25.40m
EEVIA Eevia Health Oyj	0.5x	n/a	US$1.30m
PHARM Pharmiva	0.6x	n/a	US$931.42k
REDW Redwood Pharma	0.3x	n/a	US$301.09k

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: ONCOZ is expensive based on its Price-To-Book Ratio (3.3x) compared to the Swedish Pharmaceuticals industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is ONCOZ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONCOZ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	3.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ONCOZ's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

5.0%

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

-2.7%

14.5%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

-8.1%

n/a